J. Infante

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

K. Flaherty, J. Sosman, I. Puzanov, 2012, The New England journal of medicine.

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours

A. Bryce, T. Ames, D. Camidge, 2022, EClinicalMedicine.

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

Suzanne F. Jones, E. Sausville, K. Papadopoulos, 2013, Cancer Chemotherapy and Pharmacology.

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.

R. Robles, J. Infante, M. Tortorici, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.

M. Birrer, K. Wood, B. Wolpin, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

DMD053926 2104..2113

A. Tolcher, W. Fairbrother, E. Kadel, 2013 .

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma.

M. Voss, S. Chowdhury, R. Hawkins, 2021, Clinical genitourinary cancer.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist

A. Tolcher, W. Fairbrother, E. Kadel, 2013, Drug Metabolism and Disposition.

2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)

R. Motzer, M. Voss, B. Rini, 2015 .